Form 4: Terns Pharma Director Opts for Stock Over Cash

Terns Pharmaceuticals director Jeffrey B Kindler elected to receive a stock option grant in lieu of his 2026 cash retainer fee.

Summary

• Jeffrey B Kindler, a Director of Terns Pharmaceuticals, Inc. (TERN), acquired 1,697 stock options.
• The options were granted on February 1, 2026, with an exercise price of $34.6 per share.
• This grant was in lieu of his $45,000 cash retainer fee for 2026, as per the Issuer's Non-Employee Director Compensation Policy.
• The options will vest monthly, with 1/12th of the total shares vesting on each monthly anniversary from January 1, 2026, becoming fully vested by January 1, 2027.
• The options have an expiration date of January 31, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it indicates a director's commitment to the company's long-term success by choosing equity over cash, aligning their interests with shareholders.

Positives

• Director Jeffrey B Kindler's election to receive stock options instead of cash aligns his interests more closely with those of shareholders, incentivizing long-term company performance.
• The company retains $45,000 in cash by issuing options, which can be beneficial for liquidity.

Negatives

• The issuance of stock options, even for director compensation, represents a minor potential for future share dilution if exercised.

Risks

• The value of the stock options is tied to the future performance of Terns Pharmaceuticals' stock price, meaning the director's compensation could be less than the $45,000 cash equivalent if the stock price declines.
• Shareholders face the risk of dilution if the options are exercised, though the impact from this specific grant of 1,697 shares is minimal.

Future Outlook

NA

Management Comments

• This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $45,000 for 2026.

Industry Context

StockSavvy.ai notes that the practice of non-employee directors electing to receive equity compensation (such as stock options) in lieu of cash retainers is a common and well-regarded corporate governance practice across various industries, particularly in biotechnology and high-growth sectors. This approach is often seen as a way to align the interests of directors with those of long-term shareholders.

Comparison to Industry Standards

• This compensation structure aligns with best practices observed in the biotechnology and pharmaceutical sectors, where equity-based compensation is prevalent for non-executive directors.
• Companies like Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar equity-for-cash compensation schemes for their independent directors to foster long-term commitment and performance alignment.
• The vesting schedule, with monthly vesting over a year, is also a standard approach for director equity grants, ensuring continued engagement.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Jeffrey B Kindler in lieu of a cash retainer is a related party transaction, as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also increased alignment of director's interests with long-term shareholder value.
• Director (Jeffrey B Kindler): Receives equity-based compensation, tying his personal financial outcome to the company's stock performance.
• Company (Terns Pharmaceuticals): Conserves $45,000 in cash for 2026 and strengthens director's commitment.

Next Steps

• The stock options will vest monthly, with full vesting by January 1, 2027.
• The director may choose to exercise the vested options at any time before the expiration date of January 31, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to director compensation. While it shows alignment of interests, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's a neutral event for the stock's valuation.

Keywords

Terns Pharmaceuticals, TERN, Jeffrey B Kindler, Form 4, Insider Transaction, Stock Option, Director Compensation, Equity Compensation, SEC Filing, Beneficial Ownership